AIP
ALLO icon

Ameritas Investment Partners’s Allogene Therapeutics ALLO Stock Holding History

Ameritas Investment Partners’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31.8K Hold
13,030
– – ﹤0.01% 2361
2025
Q4 		$17.9K Hold
13,030
– – ﹤0.01% 2687
2025
Q3 		$16.2K Buy
13,030
+26
+0.2% +$31 ﹤0.01% 2765
2025
Q2 		$14.7K Hold
13,004
– – ﹤0.01% 2811
2025
Q1 		$19K Hold
13,004
– – ﹤0.01% 2581
2024
Q4 		$27.7K Hold
13,004
– – ﹤0.01% 2492
2024
Q3 		$36.4K Buy
13,004
+4,900
+60% +$13.1K ﹤0.01% 2370
2024
Q2 		$18.9K Hold
8,104
– – ﹤0.01% 2642
2024
Q1 		$36.2K Hold
8,104
– – ﹤0.01% 2306
2023
Q4 		$26K Hold
8,104
– – ﹤0.01% 2468
2023
Q3 		$25.7K Buy
8,104
+2,067
+34% +$9.06K ﹤0.01% 2427
2023
Q2 		$30K Hold
6,037
– – ﹤0.01% 2333
2023
Q1 		$29.8K Hold
6,037
– – ﹤0.01% 2276
2022
Q4 		$41.4K Hold
6,037
– – ﹤0.01% 2194
2022
Q3 		$65K Hold
6,037
– – ﹤0.01% 1785
2022
Q2 		$68K Buy
6,037
+705
+13% +$6.26K ﹤0.01% 1777
2022
Q1 		$49K Hold
5,332
– – ﹤0.01% 2064
2021
Q4 		$80K Hold
5,332
– – ﹤0.01% 1815
2021
Q3 		$137K Hold
5,332
– – 0.01% 1493
2021
Q2 		$139K Buy
5,332
+738
+16% +$21K 0.01% 1517
2021
Q1 		$162K Hold
4,594
– – 0.01% 1344
2020
Q4 		$116K Hold
4,594
– – 0.01% 1493
2020
Q3 		$173K Buy
4,594
+309
+7% +$11.7K 0.01% 1108
2020
Q2 		$183K Buy
4,285
+934
+28% +$33.8K 0.01% 1059
2020
Q1 		$65K Hold
3,351
– – ﹤0.01% 1518
2019
Q4 		$87K Hold
3,351
– – ﹤0.01% 1595
2019
Q3 		$91K Hold
3,351
– – ﹤0.01% 1527
2019
Q2 		$90K Buy
3,351
+1,588
+90% +$44.2K ﹤0.01% 1560
2019
Q1 		$51K Hold
1,763
– – ﹤0.01% 1866
2018
Q4 		$47K Buy
+1,763
New +$46.8K ﹤0.01% 1844

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameritas Investment Partners's ALLO Position: Q1 2026 in Review

Ameritas Investment Partners held its Allogene Therapeutics (ALLO) position steady in Q1 2026 at 13,030 shares worth $31.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2361.

Ameritas Investment Partners first reported a position in ALLO in Q4 2018 and has held it in 30 quarters since. The position peaked at $183K in Q2 2020. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Ameritas Investment Partners held 13,030 shares of Allogene Therapeutics worth $31.8K as of Q1 2026.
  • Ameritas Investment Partners left its Allogene Therapeutics share count unchanged in Q1 2026.
  • Allogene Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #2361 holding.
  • Ameritas Investment Partners first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 30 quarters since.
  • Ameritas Investment Partners's Allogene Therapeutics position peaked at $183K in Q2 2020.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.